Getinge and Zimmer Biomet announce strategic partnership in the ASC sector
GOTHENBURG, SWEDEN AND WARSAW, IND. – July 10, 2025 – Global MedTech companies Getinge and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), today announced a strategic partnership where Zimmer Biomet will distribute Getinge’s Operating Room (OR) capital products to its Ambulatory Surgery Center (ASC) customers. This partnership creates a turnkey solution for ASC customers, who can now access Getinge’s infection control and surgical portfolio and Zimmer Biomet’s broad menu of best-in-class implants and surgical robotics from a single source.
ASCs are modern healthcare facilities focused on providing same-day surgical care, without the need for patients to stay overnight. A growing part of the U.S. healthcare landscape, more than 22.5 million procedures are performed in ASCs annually.1 The global market is projected to grow steadily, driven by cost efficiency, convenience, and advances in MedTech. For more than four decades, ASCs have demonstrated an exceptional ability to improve quality and customer service while simultaneously reducing costs.2
As part of Zimmer Biomet’s ZBX ASC Solutions offering, customers will be able to access Getinge’s infection control and surgical portfolio – surgical equipment, OR integration and lighting – with Zimmer Biomet’s industry-leading joint replacement implants and technology.
“For us, this partnership represents a significant advancement in our efforts to innovate and expand the boundaries of healthcare. We are thrilled to collaborate with Zimmer Biomet to deliver value to healthcare professionals and patients within the orthopedic ASC sector. This collaboration shows our commitment to making life-saving technology accessible to more people,” said Patricia Fitch, President of North America at Getinge.
“Together with Getinge, we’re expanding our ability to deliver a comprehensive, turnkey solution for our ASC customers – faster and more seamlessly – from a company they know and trust,” said Jehanzeb Noor, Senior Vice President, Chief Strategy, Innovation and Business Development Officer, Zimmer Biomet. “As orthopedic surgeries increasingly migrate from traditional hospital settings to ASCs, the imperative to drive efficiency, enhance patient safety, and improve clinical outcomes has never been greater. By aligning with Getinge, we’re accelerating our ability to support surgeons in advancing these priorities, while shaping the future of orthopedic care.”
The partnership will be implemented in phases, starting in the U.S., with the ambition to eventually offer the combined portfolio of ASC solutions in additional regions around the world.
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
Getinge media contacts:
Alexandra Holland, EVP Brand & Communication
Phone: +1 908 930 8661
Email: alexandra.holland@getinge.com
Tom Meevis, VP Commercial Strategy and Communications
Phone: (416) 254-5054
Email: tom.meevis@getinge.com
|
Zimmer Biomet contacts: |
|
| Investors David DeMartino 646-531-6115 david.demartino@zimmerbiomet.com |
Zach Weiner 908-591-6955 zach.weiner@zimmerbiomet.com |
1. Medicare Cost Savings - Ambulatory Surgery Center Association (ASCA)